# Vicarious Surgical (2014 – 2026)

- URL: https://girisimcikafasi.com/en/startup-graveyard/vicarious-surgical/
- Sector: Health
- Country: United States
- Total funding: $425 million
- Unicorn: yes, peak valuation $1.1 billion
- Cause of closure: Ran out of cash

## What did it do?

Vicarious Surgical was founded in Massachusetts in 2014 by Adam Sachs, Sam Khalifa and Dr Barry Greene. It was developing a surgical robot, controlled through virtual reality technology, for minimally invasive operations. The robot received FDA breakthrough device designation, and ventral hernia repair was chosen as the first target. Backed by names such as Bill Gates and Khosla Ventures, the company announced a merger with D8 Holdings in April 2021.

## Why did it shut down?

The merger announced in April 2021 valued the business at about USD 1.1 billion, yet it had nothing on sale. According to MedTech Dive, delays piled up, plans for a clinical trial were cancelled in 2025, and the new chief executive, Stephen From, scrapped them for good. Early in 2026 the New York Stock Exchange sent a delisting notice and the shares moved to the over-the-counter market. By 9 March 2026 the workforce was down to 26. On 31 March 2026 the company held USD 3.7 million in cash and warned it could not continue as a going concern. Stockholders approved the dissolution plan on 21 July 2026, with no payout expected for them.

## The story

Vicarious Surgical made a striking promise: a surgeon wearing a virtual reality headset would work as if inside a robot slipped into the patient through a small incision. Bill Gates and Khosla Ventures backed the idea, and the FDA gave the robot breakthrough device designation. In 2021 a merger with D8 Holdings put a value of about USD 1.1 billion on the company.

The trouble was that the robot never reached an operating theatre. Timelines slid, a planned clinical trial was postponed and then dropped altogether. Stephen From, who replaced co-founder Adam Sachs as chief executive, inherited very few options.

By 2026 the company had 26 employees and, on 31 March, USD 3.7 million in cash. Neither an investor nor a buyer came forward. On 21 July 2026 stockholders approved handing the assets to an assignee for the benefit of creditors.

The Vicarious story shows that in deep technology the real test is time rather than valuation. The company never won authorisation and never sold a product, yet for years it carried the costs of a listed business.

## Lessons

- When a product needs regulatory approval, the timetable belongs to the regulator. Before you go public, work out what each year of delay would cost you.
- Postponing a clinical trial protects cash in the short term but blocks the only road to approval. When you cut, protect the step that leads to revenue.
- Famous backers and a USD 1.1 billion valuation do not replace sales. With no revenue, every new round only buys time, so plan it as exactly that.

## Sources

- [Time runs out for Vicarious Surgical](https://www.medtechdive.com/news/time-runs-out-for-vicarious-surgical/825962/)
- [Vicarious Surgical Inc. Form 8-K](https://www.sec.gov/Archives/edgar/data/0001812173/000121390026080011/ea0298707-8k_vicarious.htm)
- [Vicarious Surgical Inc. Form DEF 14A](https://www.sec.gov/Archives/edgar/data/0001812173/000121390026070393/ea0295383-def14a_vicarious.htm)
- [Vicarious Surgical Inc. and D8 Holdings Corp. Announce Definitive Business Combination Agreement](https://www.biospace.com/vicarious-surgical-inc-and-d8-holdings-corp-announce-definitive-business-combination-agreement)